Beximco Pharmaceuticals Limited provided the update in relation to the delivery and supply of the Oxford University/AstraZeneca SARS-CoV-2 vaccine, AZD1222 (the Vaccine) in Bangladesh for both the Government of Bangladesh's ("GOB") mass vaccination programme, as well as for the country's private pay market. The Company has received the first five million vaccine doses from its partner Serum Institute of India Pvt. Ltd. (SII), which are being distributed exclusively by Beximco Pharma in Bangladesh as part of GOB's mass vaccination programme. The agreement with SII included a total of 30 million doses - the remaining 25 million doses will be delivered in monthly instalments until June 2021. In addition, as previously announced, the Company agreed to import a further one million doses of the vaccine from SII for sale and distribution to the private pay market in Bangladesh. However, the Company has now been informed by SII that the first instalment (500,000 doses) of this supply will be delayed following a prioritisation on supplying vaccine doses for government mass vaccination programmes and WHO-led COVAX initiatives over private pay use. It remains unclear how long this delay will last. The Company will update the market as and when appropriate.